Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 09:35 am Sale | 2024-09-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | Avoro Capital Advisors LLC | 885,059 1.700% | -954,079 (-51.88%) | Filing History |
| 2024-11-12 10:34 am Purchase | 2024-11-08 | 13G | SPYRE THERAPEUTICS, INC SYRE | FMR LLC | 7,623,881 14.999% | 1,040,726 (+15.81%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | BlackRock, Inc. BLK | 2,663,147 5.200% | 0 (Unchanged) | Filing History |
| 2024-10-23 2:10 pm Purchase | 2024-10-14 | 13G | SPYRE THERAPEUTICS, INC SYRE | Deutsch Peter E. | 3,550,276 6.990% | 3,166,617 (+825.37%) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | SPYRE THERAPEUTICS, INC SYRE | BlackRock, Inc. BLK | 2,663,147 5.200% | 2,545,440 (+2162.52%) | Filing History |
| 2024-06-10 09:48 am Sale | 2024-06-07 | 13G | SPYRE THERAPEUTICS, INC SYRE | FMR LLC | 6,583,155 12.963% | -1,020 (-0.02%) | Filing History |
| 2024-04-25 4:40 pm Purchase | 2024-04-23 | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 4,508,579 11.170% | 3,672,120 (+439.01%) | Filing History |
| 2024-04-23 6:22 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Avoro Capital Advisors LLC | 1,839,138 5.100% | -286,459 (-13.48%) | Filing History |
| 2024-03-11 08:19 am Purchase | 2024-03-08 | 13G | SPYRE THERAPEUTICS, INC SYRE | FMR LLC | 6,584,175 18.213% | 377,724 (+6.09%) | Filing History |
| 2024-02-14 8:47 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Venrock Healthcare Capital Partners III, L.P. | 3,734,514 9.990% | 3,415,314 (+1069.96%) | Filing History |
| 2024-02-14 4:51 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Nantahala Capital Management, LLC | 0 0.000% | -184,452 (Position Closed) | Filing History |
| 2024-02-14 4:37 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | EcoR1 Capital, LLC | 887,076 2.500% | 887,076 (New Position) | Filing History |
| 2024-02-14 4:27 pm Unchanged | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Perceptive Advisors LLC | 2,606,679 7.200% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | BAKER BROS. ADVISORS LP | 0 0.000% | -255,361 (Position Closed) | Filing History |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Commodore Capital LP | 1,934,084 5.400% | 100,000 (+5.45%) | Filing History |
| 2024-02-14 3:51 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Logos Global Management LP | 150,000 0.400% | -104,000 (-40.94%) | Filing History |
| 2024-02-14 2:07 pm Sale | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Rock Springs Capital Management LP | 0 0.000% | -136,556 (Position Closed) | Filing History |
| 2024-02-14 09:08 am Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Avoro Capital Advisors LLC | 2,125,597 5.900% | 2,125,597 (New Position) | Filing History |
| 2024-02-14 08:56 am Purchase | 2023-12-31 | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Deep Track Capital, LP | 2,184,440 6.030% | 1,894,118 (+652.42%) | Filing History |
| 2024-02-14 07:02 am Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | RTW Investments, LP | 2,232,760 6.200% | 2,232,760 (New Position) | Filing History |